IRIS, a randomised, double-blind, placebo-controlled trial of interleukin-6 receptor inhibition undergoing endovascular treatment in acute anterior circulation ischaemic stroke: study rationale and design
Xuehong Chu(Capital Medical University), Chuanjie Wu(Capital Medical University), Chuanhui Li(Capital Medical University), Xunming Ji(Capital Medical University), Wenbo Zhao(Zhengzhou University), Xiangyang Feng(Xintai People's Hospital), Zhengfei Ma(Suzhou Municipal Hospital), Ning Wang(National Center for Chronic and Noncommunicable Disease Control and Prevention), Chaoqun Li(Zhejiang Cancer Hospital), Jianqiao Li(Qilu Hospital of Shandong University), Yifeng Liu(Xuzhou Medical College), Jun Sun(University of Illinois Chicago), Chen Zhou(Capital Medical University), Benxiao Wang
Cited by 16
Related Papers
Stroke in China: advances and challenges in epidemiology, prevention, and management
|The Lancet Neurology|2019|1.6k
Transfer of mitochondria from astrocytes to neurons after stroke
|Nature|2016|1.4k
Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion
|New England Journal of Medicine|2022|707
Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion
|New England Journal of Medicine|2022|665
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|490